Edition:
United Kingdom

People: Atara Biotherapeutics Inc (ATRA.OQ)

ATRA.OQ on NASDAQ Stock Exchange Global Select Market

15.64USD
17 Sep 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$15.64
Open
$14.81
Day's High
$15.97
Day's Low
$14.53
Volume
218,444
Avg. Vol
276,067
52-wk High
$43.85
52-wk Low
$11.89

Berger, Dietmar 

Dr. Dietmar Berger is Global Head of Research and Development of the Company. He has served as Global Head of Research and Development since May 2018. Prior to joining Atara, from November 2011 to March 2018, Dr. Berger worked at Genentech, Inc. a Member of the Roche Group and was most recently the Senior Vice President and Global Head, Product Development, Clinical Science Hematology and Oncology. From October 2009 to November 2011, he led oncology clinical development at Bayer, and from February 1999 to October 2009 held positions of increasing responsibility at Amgen. He received the Cancer Award of the German Cancer Society for his research on angiogenesis and earned his M.D. and Ph.D. degrees from the University of Freiburg.

Basic Compensation

Total Annual Compensation, USD 748,152
Restricted Stock Award, USD 2,102,500
Long-Term Incentive Plans, USD --
All Other, USD 2,121,790
Fiscal Year Total, USD 4,972,440

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Pascal Touchon

--

Utpal Koppikar

4,220,280

Joseph Newell

2,492,290

Mina Kim

3,384,430

Derrell Porter

1,510,390

Dietmar Berger

4,972,440
As Of  31 Dec 2018